Literature DB >> 18614668

Neisseria meningitidis PorB, a Toll-like receptor 2 ligand, improves the capacity of Francisella tularensis lipopolysaccharide to protect mice against experimental tularemia.

Damiana Chiavolini1, Susan Weir, John R Murphy, Lee M Wetzler.   

Abstract

Francisella tularensis causes severe pneumonia that can be fatal if it is left untreated. Due to its potential use as a biological weapon, research is being conducted to develop an effective vaccine and to select and study adjuvant molecules able to generate a better and long-lasting protective effect. PorB, a porin from Neisseria meningitidis, is a well-established Toll-like receptor 2 ligand and has been shown to be a promising vaccine adjuvant candidate due to its ability to enhance the T-cell costimulatory activity of antigen-presenting cells both in vitro and in vivo. BALB/c mice were immunized with lipopolysaccharide (LPS) isolated from the F. tularensis subsp. holarctica live vaccine strain (LVS), with or without PorB from N. meningitidis, and the antibody levels induced during the vaccination regimen and the level of protection against intranasal challenge with LVS were determined. Antigen administered alone induced a specific F. tularensis LPS immunoglobulin M (IgM) response that was not maintained over the weeks and that conferred protection to only 25% of the mice. In contrast, F. tularensis LPS given in combination with neisserial PorB induced consistent levels of specific IgM throughout the immunization and increased the proportion of surviving mice to 70%. Postchallenge cytokine analysis showed that interleukin-6 (IL-6), monocyte chemoattractant protein 1, and gamma interferon were markers of mortality and that IL-1beta was a correlate of survival, independent of the presence of PorB as an adjuvant. These data indicate that neisserial PorB might be an optimal candidate adjuvant for improving the protective effect of F. tularensis LPS and other subunit vaccines against tularemia, but there is still a need to test its efficacy against virulent type A and type B F. tularensis strains.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18614668      PMCID: PMC2546688          DOI: 10.1128/CVI.00125-08

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  45 in total

Review 1.  Recent developments in adjuvants for vaccines against infectious diseases.

Authors:  D T O'Hagan; M L MacKichan; M Singh
Journal:  Biomol Eng       Date:  2001-10-15

Review 2.  Bacterial polysaccharide-protein conjugate vaccines.

Authors:  Adam Finn
Journal:  Br Med Bull       Date:  2004-08-31       Impact factor: 4.291

3.  TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848).

Authors:  Risini D Weeratna; Shawn R Makinen; Michael J McCluskie; Heather L Davis
Journal:  Vaccine       Date:  2005-07-18       Impact factor: 3.641

Review 4.  The perfect mix: recent progress in adjuvant research.

Authors:  Bruno Guy
Journal:  Nat Rev Microbiol       Date:  2007-07       Impact factor: 60.633

5.  The role of B/T costimulatory signals in the immunopotentiating activity of neisserial porin.

Authors:  F G Mackinnon; Y Ho; M S Blake; F Michon; A Chandraker; M H Sayegh; L M Wetzler
Journal:  J Infect Dis       Date:  1999-09       Impact factor: 5.226

6.  Inactivated Francisella tularensis live vaccine strain protects against respiratory tularemia by intranasal vaccination in an immunoglobulin A-dependent fashion.

Authors:  Shawn D Baron; Rajendra Singh; Dennis W Metzger
Journal:  Infect Immun       Date:  2007-02-12       Impact factor: 3.441

7.  Role of lipopolysaccharide and a major outer membrane protein from Francisella tularensis in the induction of immunity against tularemia.

Authors:  M Fulop; R Manchee; R Titball
Journal:  Vaccine       Date:  1995-09       Impact factor: 3.641

8.  Protection afforded against aerosol challenge by systemic immunisation with inactivated Francisella tularensis live vaccine strain (LVS).

Authors:  J E Eyles; M G Hartley; T R Laws; P C F Oyston; K F Griffin; R W Titball
Journal:  Microb Pathog       Date:  2007-08-21       Impact factor: 3.738

9.  Protection afforded by heat shock protein 60 from Francisella tularensis is due to copurified lipopolysaccharide.

Authors:  M G Hartley; M Green; G Choules; D Rogers; D G C Rees; S Newstead; A Sjostedt; R W Titball
Journal:  Infect Immun       Date:  2004-07       Impact factor: 3.441

10.  Immunogenicity and toxicity of lipopolysaccharide from Francisella tularensis LVS.

Authors:  G Sandström; A Sjöstedt; T Johansson; K Kuoppa; J C Williams
Journal:  FEMS Microbiol Immunol       Date:  1992-10
View more
  16 in total

1.  Detoxified endotoxin vaccine (J5dLPS/OMP) protects mice against lethal respiratory challenge with Francisella tularensis SchuS4.

Authors:  Stephen H Gregory; Wilbur H Chen; Stephanie Mott; John E Palardy; Nicholas A Parejo; Sara Heninger; Christine A Anderson; Andrew W Artenstein; Steven M Opal; Alan S Cross
Journal:  Vaccine       Date:  2010-02-17       Impact factor: 3.641

2.  Improvement of immunogenicity of meningococcal lipooligosaccharide by coformulation with lipidated transferrin-binding protein B in liposomes: implications for vaccine development.

Authors:  Noëlle Mistretta; Bruno Guy; Yves Bérard; François Dalençon; Olivia Fratantonio; Christophe Grégoire; Aurélie Lechevallier; Philippe Lhéritier; Laurent Revet; Monique Moreau; Jean Haensler; Bachra Rokbi
Journal:  Clin Vaccine Immunol       Date:  2012-03-21

Review 3.  Innate immune function of the neisserial porins and the relationship to vaccine adjuvant activity.

Authors:  Lee M Wetzler
Journal:  Future Microbiol       Date:  2010-05       Impact factor: 3.165

4.  The FomA porin from Fusobacterium nucleatum is a Toll-like receptor 2 agonist with immune adjuvant activity.

Authors:  Deana N Toussi; Xiuping Liu; Paola Massari
Journal:  Clin Vaccine Immunol       Date:  2012-05-23

5.  Bronchus-associated lymphoid tissue (BALT) and survival in a vaccine mouse model of tularemia.

Authors:  Damiana Chiavolini; Javier Rangel-Moreno; Gretchen Berg; Kate Christian; Laura Oliveira-Nascimento; Susan Weir; Joseph Alroy; Troy D Randall; Lee M Wetzler
Journal:  PLoS One       Date:  2010-06-16       Impact factor: 3.240

6.  Effective, broad spectrum control of virulent bacterial infections using cationic DNA liposome complexes combined with bacterial antigens.

Authors:  Robin Ireland; Norma Olivares-Zavaleta; Jonathan M Warawa; Frank C Gherardini; Clayton Jarrett; B Joseph Hinnebusch; John T Belisle; Jeffery Fairman; Catharine M Bosio
Journal:  PLoS Pathog       Date:  2010-05-27       Impact factor: 6.823

7.  Crystallographic analysis of Neisseria meningitidis PorB extracellular loops potentially implicated in TLR2 recognition.

Authors:  Christof Kattner; Deana N Toussi; Jan Zaucha; Lee M Wetzler; Nadine Rüppel; Ulrich Zachariae; Paola Massari; Mikio Tanabe
Journal:  J Struct Biol       Date:  2013-12-19       Impact factor: 2.867

Review 8.  Vaccines against tularemia.

Authors:  Eileen M Barry; Leah E Cole; Araceli E Santiago
Journal:  Hum Vaccin       Date:  2009-12-11

9.  Meningococcal PorB induces a robust and diverse antigen specific T cell response as a vaccine adjuvant.

Authors:  Munir Mosaheb; Lee M Wetzler
Journal:  Vaccine       Date:  2018-10-28       Impact factor: 3.641

10.  Saturating mutagenesis of an essential gene: a majority of the Neisseria gonorrhoeae major outer membrane porin (PorB) is mutable.

Authors:  Adrienne Chen; H Steven Seifert
Journal:  J Bacteriol       Date:  2013-11-15       Impact factor: 3.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.